The Bird Flu / Swine Flu / MRSA / SuperBug Stock Page

[cfoofme]

NanoViricides Treatments Proven Superior in Testing; Results Released at International Conference
posted Wednesday, 3 October 2007

MN1 Staff Writer

WEST HAVEN, Conn. (October 3, 2007) - NanoViricides Inc. (OTCBB: NNVC) recently presented important results regarding the company's FluCide-I and FluCide-HP treatments for influenzas.

Dr. Eugene Seymour, MD, MPH, CEO of the company commented at the 5th International Bird Flu Conference in Las Vegas: "In our completely lethal mouse model, efficacy of FluCide-I has improved significantly, and even FluCide-HP, which is designed against high path influenzas, showed very strong efficacy against H1N1, which was the cause of 1918 Spanish Flu pandemic."

NanoViricides is on the cutting edge of the battle against these influenzas, and representatives from Vietnam, Indonesia, and Turkey have made it clear to the company that no good treatment options exist currently.

Seymour relayed their sentiments in his presentation at the conference: "These speakers complained that patients sought medical care too late for Tamiflu - the drug currently recommended by the World Health Organization - to be effective. They also pointed out that resistance to Tamiflu develops quickly. Vaccines may be ineffective in the field due to the antigenic drift caused by the observed rapid mutation rate of the influenza virus, according to these physicians. They fear that antibodies alone also will be ineffective as drugs in the field due to the antigenic drift."

Included in the company's research results were findings that the improved FluCide-I is now 16X (1,600 percent) better than oseltamivir (active ingredient of TamiFlu), and FluCide-HP is 8X (800 percent) better than oseltamivir, based on dose-response comparisons.

NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

The company is also working on nanoviricides against Dengue viruses with the Walter Reed Army Institute of Research. Dengue virus is currently causing the worst outbreak in several years in Latin America, and has already crossed the border into the U.S.

NanoViricides is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.

http://feeds.mn1.com/nanoviricides_treatments_proven_superior_in_testing_results.htm